Italiano
About CTI
About CTI - Management
About CTI - Board of Directors
About CTI - In the Community
Partnering with CTI
Clinical Development
Pixantrone (PIXUVRI®)
Pacritinib
Tosedostat
Paclitaxel poliglumex (Opaxio™)
Brostallicin
Medical Presentations & Publications
Medical Inquiries for Healthcare Professionals
Medical Inquiries for Patients and Caregivers
Media
News
Investors
News
Stock
SEC Filings
Analyst Coverage
Presentations & Webcasts
Annual Reports
Financial Details
Corporate Governance
Investor FAQ
Information Request
Email Alerts
Careers
Benefits
Job Opportunities
Contact CTI
Directions
Event Details
Tweet
News
Stock
SEC Filings
Analyst Coverage
Presentations & Webcasts
Annual Reports
Financial Details
Corporate Governance
Investor FAQ
Information Request
Email Alerts
Info Tools
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
IR Contacts
Tear Sheet
Most Viewed Links
1.
CTI Announces Data Presentations at the 18th Congress of the European Hematology Association
2.
SEC Filings
3.
CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
4.
Stock Quote
5.
New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRI® in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment
You are now leaving this website. If you would like to continue, click Continue.
Cancel
Continue
